OpenURL Connection Search

Select item for more details and to access through your institution.

Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
Published in:
PLoS ONE, 2015, v. 10, n. 9, p. 1, doi. 10.1371/journal.pone.0137345
By:
- Liu, Jie;
- Wang, Lijuan;
- Zhao, Feifei;
- Tseng, Serena;
- Narayanan, Cyndhavi;
- Shura, Lei;
- Willingham, Stephen;
- Howard, Maureen;
- Prohaska, Susan;
- Volkmer, Jens;
- Chao, Mark;
- Weissman, Irving L.;
- Majeti, Ravindra
Publication type:
Article
Learning from Host-Defense Peptides: Cationic, Amphipathic Peptoids with Potent Anticancer Activity.
Published in:
PLoS ONE, 2014, v. 9, n. 2, p. 1, doi. 10.1371/journal.pone.0090397
By:
- Huang, Wei;
- Seo, Jiwon;
- Willingham, Stephen B.;
- Czyzewski, Ann M.;
- Gonzalgo, Mark L.;
- Weissman, Irving L.;
- Barron, Annelise E.
Publication type:
Article
NLRs at the intersection of cell death and immunity.
Published in:
Nature Reviews Immunology, 2008, v. 8, n. 5, p. 372, doi. 10.1038/nri2296
By:
- Ting, Jenny P.-Y.;
- Willingham, Stephen B.;
- Bergstralh, Daniel T.
Publication type:
Article
NLRs and the dangers of pollution and aging.
Published in:
Nature Immunology, 2008, v. 9, n. 8, p. 831, doi. 10.1038/ni0808-831
By:
- Willingham, Stephen B;
- Ting, Jenny P-Y
Publication type:
Article
A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer.
Published in:
Nature Communications, 2017, v. 8, n. 4, p. 14802, doi. 10.1038/ncomms14802
By:
- Betancur, Paola A.;
- Abraham, Brian J.;
- Yiu, Ying Y.;
- Willingham, Stephen B.;
- Khameneh, Farnaz;
- Zarnegar, Mark;
- Kuo, Angera H.;
- McKenna, Kelly;
- Kojima, Yoko;
- Leeper, Nicholas J.;
- Ho, Po;
- Gip, Phung;
- Swigut, Tomek;
- Sherwood, Richard I.;
- Clarke, Michael F.;
- Somlo, George;
- Young, Richard A.;
- Weissman, Irving L.
Publication type:
Article
Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.
Published in:
Science Translational Medicine, 2017, v. 9, n. 381, p. 1, doi. 10.1126/scitranslmed.aaf2968
By:
- Gholamin, Sharareh;
- Mitra, Siddhartha S.;
- Feroze, Abdullah H.;
- Jie Liu;
- Kahn, Suzana A.;
- Zhang, Michael;
- Esparza, Rogelio;
- Richard, Chase;
- Ramaswamy, Vijay;
- Remke, Marc;
- Volkmer, Anne K.;
- Willingham, Stephen;
- Ponnuswami, Anitha;
- McCarty, Aaron;
- Lovelace, Patricia;
- Storm, Theresa A.;
- Schubert, Simone;
- Hutter, Gregor;
- Narayanan, Cyndhavi;
- Chu, Pauline
Publication type:
Article
Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47.
Published in:
Science Translational Medicine, 2010, v. 2, n. 63, p. 1, doi. 10.1126/scitranslmed.3001375
By:
- Chao, Mark P.;
- Jaiswal, Siddhartha;
- Weissman-Tsukamoto, Rachel;
- Alizadeh, Ash A.;
- Gentles, Andrew J.;
- Volkmer, Jens;
- Weiskopf, Kipp;
- Willingham, Stephen B.;
- Raveh, Tal;
- Park, Christopher Y.;
- Majeti, Ravindra;
- Weissman, Irving L.
Publication type:
Article

Found: 7

Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.

Learning from Host-Defense Peptides: Cationic, Amphipathic Peptoids with Potent Anticancer Activity.

NLRs at the intersection of cell death and immunity.

NLRs and the dangers of pollution and aging.

A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer.

Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.

Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47.